Gene Expression Profile-Guided Personalized Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Carcinomatosis

Vitaly A Markovich; Sergey A Tuzikov; Evgeny O Rodionov; Natalia O Popova; Matvey M Tsyganov; Sergey V Miller; Danil V Podolko; Irina A Tsydenova; Marina K Ibragimova; Nikolai V Litviakov

doi:10.14740/wjon1578

Gene Expression Profile-Guided Personalized Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Carcinomatosis

World J Oncol. 2024 Apr;15(2):298-308. doi: 10.14740/wjon1578. Epub 2024 Mar 21.

Authors

Vitaly A Markovich¹, Sergey A Tuzikov^{1

2

3}, Evgeny O Rodionov^{1

2}, Natalia O Popova¹, Matvey M Tsyganov^{1

4}, Sergey V Miller¹, Danil V Podolko¹, Irina A Tsydenova^{1

4}, Marina K Ibragimova^{1

2

4}, Nikolai V Litviakov^{1

4}

Affiliations

¹ Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia.
² Siberian State Medical University, Tomsk, Russia.
³ Deceased.
⁴ National Research Tomsk State University, Tomsk, Russia.

Abstract

Background: Peritoneal carcinomatosis (PC) is one of the most unfavorable sites of metastasis for malignant tumors of various localizations, especially gastric cancer (GC). According to the literature, synchronous PC in GC is common in 15-52% of patients. The purpose of this study was to examine the long-term results using personalized systemic and intraperitoneal chemotherapy as part of the combined treatment of stomach cancer presenting with synchronous PC.

Methods: Cytoreductive surgical treatment was performed for 70 patients at the first stage. The control group (n = 35) received standard postoperative chemotherapy according to the FOLFOX scheme. Personalized postoperative systemic and intraperitoneal chemotherapy was administered in the basic group (n = 35), based on the expression levels of the eight genes in the primary tumor, lymph node, and peritoneal metastases.

Results: The median progression-free survival was 14.9 months in the basic group, and in the control group it was 11.2 months (P < 0.001). The median life expectancy in the basic group was 16.8 (13.7 - 18.8) months, in the control group it was 12.5 (11.3 - 13.1) months (P < 0.001).

Conclusions: Developing algorithms of personalized systemic and intraperitoneal chemotherapy in patients with GC with synchronous carcinomatosis, based on the analysis of molecular genetic characteristics of the tumor and metastases, allows to improve the long-term results of combined treatment.

Keywords: Cytoreductive surgery; Monoresistance genes; Peritoneal carcinomatosis; Personalized systemic and intraperitoneal chemotherapy.

Grants and funding

State contract of the Ministry of Science and Higher Education of the Russian Federation “Genetic and epigenetic editing of tumor cells and microenvironment in order to block metastasis” No. 075-15-2021-1073.